Cumberland Pharmaceuticals Files 8-K for Other Events
Ticker: CPIX · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1087294
Sentiment: neutral
Topics: other-events, sec-filing
Related Tickers: CPRX
TL;DR
CPRX filed an 8-K for 'Other Events' on 12/9/24 - details TBD.
AI Summary
Cumberland Pharmaceuticals Inc. filed an 8-K on December 9, 2024, to report "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself. Further information would be required to understand the specific business or financial implications.
Why It Matters
This filing indicates that Cumberland Pharmaceuticals Inc. has reported an event requiring disclosure to the SEC, but the lack of specific details makes it impossible to assess its immediate impact.
Risk Assessment
Risk Level: medium — The risk level is medium due to the lack of specific information in the 8-K filing, which creates uncertainty about the nature and potential impact of the reported 'Other Events'.
Key Players & Entities
- CUMBERLAND PHARMACEUTICALS INC. (company) — Registrant
- December 9, 2024 (date) — Filing Date
FAQ
What specific 'Other Events' are being reported by Cumberland Pharmaceuticals Inc. in this 8-K filing?
The provided filing text does not specify the nature of the 'Other Events' beyond the general category.
Are there any financial implications or dollar amounts associated with the reported 'Other Events'?
The filing text does not mention any specific dollar amounts or financial figures related to the 'Other Events'.
What is the significance of the filing date of December 9, 2024?
December 9, 2024, is the date the 8-K form was filed with the SEC and the date of the earliest event reported.
What is Cumberland Pharmaceuticals Inc.'s principal executive office address?
The principal executive offices are located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203.
What is Cumberland Pharmaceuticals Inc.'s telephone number?
The registrant's telephone number, including area code, is (615) 255-0068.
Filing Stats: 456 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-12-09 17:04:00
Filing Documents
- cpix-20241209.htm (8-K) — 27KB
- acetadote2bagstudy12924.htm (EX-99.1) — 23KB
- image_0.jpg (GRAPHIC) — 24KB
- 0001628280-24-050499.txt ( ) — 210KB
- cpix-20241209.xsd (EX-101.SCH) — 2KB
- cpix-20241209_lab.xml (EX-101.LAB) — 21KB
- cpix-20241209_pre.xml (EX-101.PRE) — 12KB
- cpix-20241209_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On December 9, 2024, Cumberland Pharmaceuticals Inc. ("Cumberland" or the "Company") announced the U. S. Food and Drug Administration ("FDA") has approved a supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen 1 . The newly approved dosing regimen simplifies the administration of Acetadote by combining the first two bags of the standard regimen into a single, slower infusion. A copy of the release is furnished as Exhibit 99.1 . Exhibit No. Description 99.1 Press release dated December 9, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: December 9, 2024 By: /s/ John Hamm John Hamm Chief Financial Officer